Document is current
Any future updates will be listed below
-
Authors
Bontoux, Christophe
Lacoux, Caroline
Benzaquen, Jonathan
Boutros, Jacques
Rignol, Guylène
Long-Mira, Elodie
Lassalle, Sandra
Allegra, Maryline
Bohly, Doriane
Garcia, Mathieu
Bonnetaud, Christelle
Bordone, Olivier
Félix, Jean-Marc
Lespinet-Fabre, Virginie
Tanga, Virginie
Marquette, Charles-Hugo
Taly, Valérie
Baurès, Aurélia
Heeke, Simon
Ilié, Marius
Hofman, Véronique
Hofman, Paul
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (#ANR-23-IHU-007)
Hedera DX
- License Information
-
More Information
Article History
Received: 27 March 2025
Accepted: 14 July 2025
First Online: 6 August 2025
Declarations
:
: All patients signed an informed consent to participate in the study. The study was conducted in accordance with the Declaration of Helsinki, and approved by the ethical committee of Nice Hospital University (NPPS-101188).
: -Marius IliéHonoraria: AstraZeneca, Merck; Speakers’ Bureau: AstraZeneca; Research Funding: Bristol Myers Squibb, Boehringer Ingelheim; Travel, Accommodations, Expenses: AstraZeneca. -Simon Heeke: Employment: Marker Therapeutics; Honoraria: Qiagen; Consulting or Advisory Role: Boehringer Ingelheim; Speakers’ Bureau: AstraZeneca, Guardant Health; Patents, Royalties, Other Intellectual Property: Patent on the Treatment of Lung Cancer; Travel, Accommodations, Expenses: Roche. -Paul Hofman: Honoraria: Sanofi, Amgen, Roche, BMS, AstraZeneca, AbbVie, Qiagen, Pfizer, Janssen, Pierre Fabre, Thermo Fisher Scientific, Biodena, Diaceutics, Biocartis, Daiichi Sankyo/Lilly, Bayer, Novartis; Consulting or Advisory Role: Sanofi, Amgen, Roche, AbbVie, BMS, AstraZeneca, Pfizer, Janssen, Pierre Fabre, Thermo Fisher Scientific, Qiagen, Diaceutics, Novartis, Biodena, Biocartis, Lilly; Research Funding: Amgen, Thermo Fisher Scientific, Biodena, Roche. No other potential conflicts of interest were reported.
